With 1.66 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.37 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.04 whereas the lowest price it dropped to was $3.17. The 52-week range on GNTA shows that it touched its highest point at $10.00 and its lowest point at $2.56 during that stretch. It currently has a 1-year price target of $20.87. Beta for the stock currently stands at 0.59.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GNTA was up-trending over the past week, with a rise of 3.75%, but this was up by 5.06% over a month. Three-month performance dropped to -10.31% while six-month performance fell -13.32%. The stock lost -23.68% in the past year, while it has lost -39.64% so far this year. A look at the trailing 12-month EPS for GNTA yields -0.51 with Next year EPS estimates of -0.87. EPS is expected to decline by -12.56% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -13.19%.
Float and Shares Shorts:
On 2025-10-15, short shares totaled 976.0, which was 1.0 higher than short shares on 1757894400. In addition to Mr. Pierluigi Paracchi as the firm’s Co-Founder, Chairman, CEO & GM, Dr. Luigi Naldini M.D., Ph.D. serves as its Co-Founder & Chairman of Scientific Advisory Board.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GNTA since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GNTA analysts setting a high price target of 24.819866 and a low target of 20.838287, the average target price over the next 12 months is 22.829077. Based on these targets, GNTA could surge 647.59% to reach the target high and rise by 527.66% to reach the target low. Reaching the average price target will result in a growth of 587.62% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.47986 being high and -$0.47986 being low. For GNTA, this leads to a yearly average estimate of -$0.47986.
